AveXis, Inc. (NASDAQ:AVXS)‘s stock had its “outperform” rating restated by equities researchers at BMO Capital Markets in a note issued to investors on Saturday. They presently have a $123.00 price objective on the stock. BMO Capital Markets’ price target indicates a potential upside of 27.16% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Jefferies Group LLC reissued a “buy” rating and set a $108.00 price target (up from $92.00) on shares of AveXis in a report on Friday, August 11th. Chardan Capital reissued a “buy” rating and set a $130.00 price target (up from $102.50) on shares of AveXis in a report on Friday, August 11th. Citigroup Inc. set a $100.00 price target on shares of AveXis and gave the stock a “buy” rating in a report on Thursday, June 15th. Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, William Blair started coverage on shares of AveXis in a report on Wednesday, August 23rd. They set an “outperform” rating and a $107.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. AveXis has an average rating of “Buy” and a consensus target price of $99.29.

Shares of AveXis (AVXS) traded up 4.92% during trading on Friday, reaching $96.73. The company had a trading volume of 1,332,318 shares. The firm has a 50-day moving average of $93.16 and a 200 day moving average of $80.70. AveXis has a 1-year low of $38.46 and a 1-year high of $101.67. The firm’s market capitalization is $3.09 billion.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same period in the previous year, the firm earned ($0.68) EPS. Analysts expect that AveXis will post ($6.04) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/30/bmo-capital-markets-reaffirms-outperform-rating-for-avexis-inc-avxs.html.

In other news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $91.52, for a total value of $162,905.60. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at $162,905.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 5,340 shares of company stock worth $474,637 over the last quarter. Company insiders own 18.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC acquired a new stake in shares of AveXis in the second quarter valued at approximately $20,614,000. Ameritas Investment Partners Inc. grew its position in shares of AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the last quarter. California State Teachers Retirement System grew its position in shares of AveXis by 280.6% in the second quarter. California State Teachers Retirement System now owns 43,538 shares of the company’s stock valued at $3,577,000 after purchasing an additional 32,100 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of AveXis by 210.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,961 shares of the company’s stock valued at $1,312,000 after purchasing an additional 10,827 shares during the last quarter. Finally, PointState Capital LP grew its position in shares of AveXis by 118.7% in the second quarter. PointState Capital LP now owns 544,667 shares of the company’s stock valued at $44,750,000 after purchasing an additional 295,600 shares during the last quarter. Institutional investors and hedge funds own 94.71% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.